MedTrace Logo

Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression

NCT07324070 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-07

No results posted yet for this study

Summary

The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation. Subject will be compared both within groups and in group using psychometric scales and different deliver energy

Conditions

  • Major Depressive Disorder (MDD)
  • Treatment Resistant Depression (TRD)

Interventions

DEVICE

Electroconvulsive therapy

transcranial magnetic stimulation in intermitent theta burst stimulation protocol plus electroconvulsive therapy

DEVICE

Transcranial Magnetic Stimulation

Transcranial magnetic stimulation, intermitent theta burst stimulation or sham TMS

Sponsors & Collaborators

  • Charles University, Czech Republic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2028-01-05
Completion
2029-01-05
FDA Device
Yes

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07324070 on ClinicalTrials.gov